CoChat

Stem cell–derived models to improve mechanistic understanding and prediction of human drug‐induced liver injury

Open access
Goldring, Christopher, Antoine, Daniel J., Bonner, Frank, Crozier, Jonathan, Denning, Chris, Fontana, Robert J., Hanley, Neil A., Hay, David C., Ingelman‐Sundberg, Magnus, Juhila, Satu, Kitteringham, Neil, Silva‐Lima, Beatriz, Norris, Alan, Pridgeon, Chris, Ross, James A., Young, Rowena Sison, Tagle, Danilo, Tornesi, Belen, van de Water, Bob, Weaver, Richard J., Zhang, Fang, Park, B. Kevin · 2017 · Hepatology
Cited by 58

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Current preclinical drug testing does not predict some forms of adverse drug reactions in humans. Efforts at improving predictability of drug‐induced tissue injury in humans include using stem cell technology to generate human cells for screening for adverse effects of drugs in humans. The advent of induced pluripotent stem cells means that it may ultimately be possible to develop personalized toxicology to determine interindividual susceptibility to adverse drug reactions. However, the complexity of idiosyncratic drug‐induced liver injury means that no current single‐cell model, whether of primary liver tissue origin, from liver cell lines, or derived from stem cells, adequately emulates what is believed to occur during human drug‐induced liver injury. Nevertheless, a single‐cell model of a human hepatocyte which emulates key features of a hepatocyte is likely to be valuable in assessing potential chemical risk; furthermore, understanding how to generate a relevant hepatocyte will also be critical to efforts to build complex multicellular models of the liver. Currently, hepatocyte‐like cells differentiated from stem cells still fall short of recapitulating the full mature hepatocellular phenotype. Therefore, we convened a number of experts from the areas of preclinical and clinical hepatotoxicity and safety assessment, from industry, academia, and regulatory bodies, to specifically explore the application of stem cells in hepatotoxicity safety assessment and to make recommendations for the way forward. In this short review, we particularly discuss the importance of benchmarking stem cell–derived hepatocyte‐like cells to their terminally differentiated human counterparts using defined phenotyping, to make sure the cells are relevant and comparable between labs, and outline why this process is essential before the cells are introduced into chemical safety assessment. (H epatology 2017;65:710‐721).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.28886

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 64

  1. 2004, Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients, BMJ, 329, 15, 10.1136/bmj.329.7456.15 · DOI · Paper page
  2. 2008, Species concordance for liver injury, BioWisdom
  3. 2009, Diagnosis, management and prevention of drug‐induced liver injury, Gut, 58, 1555, 10.1136/gut.2008.163675 · DOI · Paper page
  4. 2012, Development of a multiparametric cell‐based protocol to screen and classify the hepatotoxicity potential of drugs, Toxicol Sci, 127, 187, 10.1093/toxsci/kfs083 · DOI · Paper page
  5. 2008, Cellular imaging predictions of clinical drug‐induced liver injury, Toxicol Sci, 105, 97, 10.1093/toxsci/kfn109 · DOI · Paper page
  6. 2016, Human upcyte hepatocytes: characterization of the hepatic phenotype and evaluation for acute and long‐term hepatotoxicity routine testing, Toxicol Sci, 152, 214, 10.1093/toxsci/kfw078 · DOI · Paper page
  7. 2013, Use of micropatterned cocultures to detect compounds that cause drug‐induced liver injury in humans, Toxicol Sci, 132, 107, 10.1093/toxsci/kfs326 · DOI · Paper page
  8. 2012, Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins, Cell Biol Toxicol, 28, 69, 10.1007/s10565-011-9208-4 · DOI · Paper page
  9. 2007, The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics, Chem Biol Interact, 168, 66, 10.1016/j.cbi.2006.12.003 · DOI · Paper page
  10. 2015, Phenotypic and functional analyses show stem cell‐derived hepatocyte‐like cells better mimic fetal rather than adult hepatocytes, J Hepatol, 62, 581, 10.1016/j.jhep.2014.10.016 · DOI · Paper page
  11. 2015, Recombinant laminins drive the differentiation and self‐organization of hESC‐derived hepatocytes, Stem Cell Reports, 5, 1250, 10.1016/j.stemcr.2015.10.016 · DOI · Paper page
  12. 2015, Gene networks and transcription factor motifs defining the differentiation of stem cells into hepatocyte‐like cells, J Hepatol, 63, 934, 10.1016/j.jhep.2015.05.013 · DOI · Paper page
  13. 2015, Efficient episomal reprogramming of blood mononuclear cells and differentiation to hepatocytes with functional drug metabolism, Exp Cell Res, 338, 203, 10.1016/j.yexcr.2015.08.004 · DOI
  14. 2013, Stem cell‐derived hepatocytes as a predictive model for drug‐induced liver injury: are we there yet?, Br J Clin Pharmacol, 75, 885, 10.1111/j.1365-2125.2012.04360.x · DOI · Paper page
  15. 2007, Directed differentiation of human embryonic stem cells into functional hepatic cells, Hepatology, 45, 1229, 10.1002/hep.21582 · DOI · Paper page
  16. 2007, Expression of drug metabolizing enzymes in hepatocyte‐like cells derived from human embryonic stem cells, Biochem Pharmacol, 74, 496, 10.1016/j.bcp.2007.05.009 · DOI
  17. 2007, Glutathione transferases in hepatocyte‐like cells derived from human embryonic stem cells, Toxicol In Vitro, 21, 929, 10.1016/j.tiv.2007.01.021 · DOI
  18. 2008, Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling, Proc Natl Acad Sci USA, 105, 12301, 10.1073/pnas.0806522105 · DOI · Paper page
  19. 2008, Differentiation of mouse and human embryonic stem cells into hepatic lineages, Genes Cells, 13, 731, 10.1111/j.1365-2443.2008.01201.x · DOI · Paper page
  20. 2008, Efficient differentiation of functional hepatocytes from human embryonic stem cells, Stem Cells, 26, 1117, 10.1634/stemcells.2007-1102 · DOI · Paper page
  21. 2009, Expedited growth factor‐mediated specification of human embryonic stem cells toward the hepatic lineage, Stem Cell Res, 3, 51, 10.1016/j.scr.2009.04.004 · DOI
  22. 2009, Differentiation and transplantation of human embryonic stem cell‐derived hepatocytes, Gastroenterology, 136, 990, 10.1053/j.gastro.2008.10.047 · DOI · Paper page
  23. 2009, Efficient generation of hepatocyte‐like cells from human induced pluripotent stem cells, Cell Res, 19, 1233, 10.1038/cr.2009.107 · DOI · Paper page
  24. 2010, Differentiation and characterization of metabolically functioning hepatocytes from human embryonic stem cells, Stem Cells, 28, 674, 10.1002/stem.315 · DOI · Paper page
  25. 2010, Transcriptional profiling of human embryonic stem cells differentiating to definitive and primitive endoderm and further toward the hepatic lineage, Stem Cells Dev, 19, 961, 10.1089/scd.2009.0220 · DOI
  26. 2010, Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development, Hepatology, 51, 1754, 10.1002/hep.23506 · DOI · Paper page
  27. 2010, Hepatocyte‐like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage, J Biotechnol, 145, 284, 10.1016/j.jbiotec.2009.11.007 · DOI
  28. 2010, Generation of liver disease‐specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte‐like cells, Stem Cell Rev, 6, 622, 10.1007/s12015-010-9189-3 · DOI
  29. 2010, Generation of endoderm‐derived human induced pluripotent stem cells from primary hepatocytes, Hepatology, 51, 1810, 10.1002/hep.23626 · DOI · Paper page
  30. 2010, Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells, J Clin Invest, 120, 3127, 10.1172/JCI43122 · DOI · Paper page
  31. 2011, Rescue of ATP7B function in hepatocyte‐like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin, Hum Mol Genet, 20, 3176, 10.1093/hmg/ddr223 · DOI · Paper page
  32. 2011, A novel chemically directed route for the generation of definitive endoderm from human embryonic stem cells based on inhibition of GSK‐3, J Cell Sci, 124, 1992, 10.1242/jcs.081679 · DOI
  33. 2011, Human embryonic stem cell derived hepatocyte‐like cells as a tool for in vitro hazard assessment of chemical carcinogenicity, Toxicol Sci, 124, 278, 10.1093/toxsci/kfr225 · DOI
  34. 2012, JD induced pluripotent stem cell‐derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia, Hepatology, 56, 2163, 10.1002/hep.25871 · DOI · Paper page
  35. 2012, Modeling hepatitis C virus infection using human induced pluripotent stem cells, Proc Natl Acad Sci USA, 109, 2544, 10.1073/pnas.1121400109 · DOI · Paper page
  36. 2012, Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4alpha transduction, Mol Ther, 20, 127, 10.1038/mt.2011.234 · DOI · Paper page
  37. 2013, Efficient drug screening and gene correction for treating liver disease using patient‐specific stem cells, Hepatology, 57, 2458, 10.1002/hep.26237 · DOI · Paper page
  38. 2013, Application of three‐dimensional culture conditions to human embryonic stem cell‐derived definitive endoderm cells enhances hepatocyte differentiation and functionality, Tissue Eng Part A, 19, 360, 10.1089/ten.tea.2012.0190 · DOI · Paper page
  39. 2014, Maturation of induced pluripotent stem cell derived hepatocytes by 3D‐culture, PLoS One, 9, e86372, 10.1371/journal.pone.0086372 · DOI · Paper page
  40. 2014, Modeling of hemophilia A using patient‐specific induced pluripotent stem cells derived from urine cells, Life Sci, 108, 22, 10.1016/j.lfs.2014.05.004 · DOI
  41. 2015, Synergistic effects of carboxymethyl‐hexanoyl chitosan, cationic polyurethane‐short branch PEI in miR122 gene delivery: accelerated differentiation of iPSCs into mature hepatocyte‐like cells and improved stem cell therapy in a hepatic failure model, Acta Biomater, 13, 228, 10.1016/j.actbio.2014.11.018 · DOI
  42. 2013, Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells, Biochem Pharmacol, 86, 691, 10.1016/j.bcp.2013.06.029 · DOI
  43. 2014, Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS‐derived hepatocytes, Proc Natl Acad Sci USA, 111, 16772, 10.1073/pnas.1413481111 · DOI · Paper page
  44. 2011, Managing the challenge of chemically reactive metabolites in drug development, Nat Rev Drug Discov, 10, 292, 10.1038/nrd3408 · DOI · Paper page
  45. 2015, Enhancing the functional maturity of induced pluripotent stem cell‐derived human hepatocytes by controlled presentation of cell‐cell interactions in vitro, Hepatology, 61, 1370, 10.1002/hep.27621 · DOI · Paper page
  46. 2015, Stem cell‐derived liver cells for drug testing and disease modeling, Discov Med, 19, 349
  47. 2011, Targeted gene correction of alpha1‐antitrypsin deficiency in induced pluripotent stem cells, Nature, 478, 391, 10.1038/nature10424 · DOI · Paper page
  48. 2015, Prediction of drug‐induced liver injury in micropatterned co‐cultures containing iPSC‐derived human hepatocytes, Toxicol Sci, 145, 252, 10.1093/toxsci/kfv048 · DOI · Paper page
  49. 2012, Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture, Dis Model Mech, 5, 220, 10.1242/dmm.008409 · DOI · Paper page
  50. 2012, Modeling of catecholaminergic polymorphic ventricular tachycardia with patient‐specific human‐induced pluripotent stem cells, J Am Coll Cardiol, 60, 990, 10.1016/j.jacc.2012.02.066 · DOI · Paper page
  51. 2011, Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes, Nat Rev Drug Discov, 10, 111, 10.1038/nrd3252 · DOI · Paper page
  52. 2014, Aggregate culture of human embryonic stem cell‐derived hepatocytes in suspension are an improved in vitro model for drug metabolism and toxicity testing, Toxicol Sci, 140, 236, 10.1093/toxsci/kfu069 · DOI
  53. 2013, Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells, Stem Cells Transl Med, 2, 409, 10.5966/sctm.2012-0160 · DOI · Paper page
  54. 2009, Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics, J Chromatogr B Analyt Technol Biomed Life Sci, 877, 1229, 10.1016/j.jchromb.2008.11.013 · DOI · Paper page
  55. 2011, Circulating microRNAs as potential markers of human drug‐induced liver injury, Hepatology, 54, 1767, 10.1002/hep.24538 · DOI · Paper page
  56. 2014, Building shared experience to advance practical application of pathway‐based toxicology: liver toxicity mode‐of‐action, ALTEX, 31, 500
  57. 2016, Activation of the Nrf2 response by intrinsic hepatotoxic drugs correlates with suppression of NF‐kappaB activation and sensitizes toward TNFalpha‐induced cytotoxicity, Arch Toxicol, 90, 1163, 10.1007/s00204-015-1536-3 · DOI
  58. 2014, Drug‐induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFalpha‐mediated hepatotoxicity, Toxicol Sci, 140, 144, 10.1093/toxsci/kfu072 · DOI · Paper page
  59. 2014, Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety assessment, Chem Res Toxicol, 27, 338, 10.1021/tx4004038 · DOI · Paper page
  60. 1998, Probing heterotypic cell interactions: hepatocyte function in microfabricated co‐cultures, J Biomater Sci Polym Ed, 9, 1137, 10.1163/156856298X00695 · DOI · Paper page
  61. 2006, Hepatocyte and Kupffer cells co‐cultured on micropatterned surfaces to optimize hepatocyte function, Tissue Eng, 12, 751, 10.1089/ten.2006.12.751 · DOI · Paper page
  62. 2002, Dedifferentiation of atrial cardiomyocytes: from in vivo to in vitro, Cardiovasc Res, 55, 9, 10.1016/S0008-6363(02)00434-0 · doi:10.1016/s0008-6363(02)00434-0
  63. 2016, Deterministically patterned biomimetic human iPSC‐derived hepatic model via rapid 3D bioprinting, Proc Natl Acad Sci USA, 113, 2206, 10.1073/pnas.1524510113 · DOI · Paper page
  64. 2015, Establishment of a hepatocyte‐Kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters, Drug Metab Dispos, 43, 774, 10.1124/dmd.114.061317 · DOI

Cited by

Metadata

Authors
Goldring, C., Antoine, D. J., Bonner, F., Crozier, J., Denning, C., Fontana, R. J., Hanley, N. A., Hay, D. C., Ingelman‐Sundberg, M., Juhila, S., Kitteringham, N., Silva‐Lima, B., Norris, A., Pridgeon, C., Ross, J. A., Young, R. S., Tagle, D., Tornesi, B., van de Water, B., Weaver, R. J., Zhang, F., & Park, B. K.
Venue
Hepatology
Published
2016-11-30
Volume
65
Issue
2
Pages
710-721
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2519164774
Cited by
58
References
14
FWCI
12.96
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.